How South Carolina Became the Southeast’s Fastest Growing Biotech Hub
Sponsored content brought to you by South Carolina just landed a $1.5 billion investment and more than 1,200 jobs, as Octapharma Plasma relocates its U.S. headquarters from Charlotte to Rock Hill and […] The post How South Carolina Became the Southeast’s Fastest Growing Biotech Hub appeared first on GEN - Genetic Engineering and Biotechnology News .
South Carolina has quickly emerged as one of the Southeast's fastest-growing biotech hubs, as evidenced by its inclusion on GEN's Next10 Emerging Biotech Hubs list. This growth can be attributed to a combination of factors, including a business-friendly climate, a strong talent pipeline, and quality of life.
One of the key drivers of this growth is the relocation of Octapharma Plasma's U.S. headquarters to Rock Hill, South Carolina. The company's investment of $1.5 billion and creation of over 1,200 jobs is a testament to the state's appeal to established manufacturers looking to expand. This move is part of a larger trend, with other manufacturers choosing South Carolina over more established hubs due to the state's talent, favorable business environment, and high quality of life.
Charleston, in particular, has become a hotspot for biotech development. SHL Medical, for instance, recently opened a $220 million facility that will create 300 jobs, producing drug delivery devices for pharmaceutical partners worldwide. The city is also home to Charles River Laboratories, which has expanded its operations with advanced cleanroom and automation capabilities.
In Columbia, the Ritedose Corporation is set to produce over two billion doses per year with its new distribution center, a $81 million investment that has created 100 additional jobs.
The foundation for this biotech growth lies in South Carolina's research universities. Clemson University's Institute for Human Genetics and Biomedical Engineering Innovation Campus are at the forefront of precision medicine and bioengineering, attracting top talent and fostering innovation. The Medical University of South Carolina, the state's only NCI-Designated Cancer Center, is attracting nationally-recognized researchers and federal funding, with plans to double its research faculty and build a new facility for its cellular therapy program.
South Carolina's life sciences ecosystem is also attracting companies that initially established themselves elsewhere. GNQ Insilico, a Greenville-based techbio company, recently moved its U.S. headquarters and lab from Silicon Valley, stating their commitment to building something enduring in the state. This trend underscores the long-term potential of South Carolina as a biotech hub.
The state's success in attracting biotech companies is also being driven by public-private partnerships. Drive, an accelerator powered by SCbio and MassBio, has supported 70 early-stage companies that have raised $137 million and created nearly 100 jobs since its launch in 2022. These companies are likely to expand within the state, further solidifying South Carolina's position as a leading biotech hub.
The window to invest in South Carolina's biotech sector is now, before the state becomes too established. With its combination of talent, business-friendly climate, and quality of life, South Carolina is building the life and science that will propel the future.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
